167 related articles for article (PubMed ID: 36724515)
1. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML.
de Botton S; Fenaux P; Yee K; Récher C; Wei AH; Montesinos P; Taussig DC; Pigneux A; Braun T; Curti A; Grove C; Jonas BA; Khwaja A; Legrand O; Peterlin P; Arnan M; Blum W; Cilloni D; Hiwase DK; Jurcic JG; Krauter J; Thomas X; Watts JM; Yang J; Polyanskaya O; Brevard J; Sweeney J; Barrett E; Cortes J
Blood Adv; 2023 Jul; 7(13):3117-3127. PubMed ID: 36724515
[TBL] [Abstract][Full Text] [Related]
2. Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
Cortes JE
Expert Rev Hematol; 2024 Jun; 17(6):211-221. PubMed ID: 38747392
[TBL] [Abstract][Full Text] [Related]
3. Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
DiNardo CD; Stein EM; de Botton S; Roboz GJ; Altman JK; Mims AS; Swords R; Collins RH; Mannis GN; Pollyea DA; Donnellan W; Fathi AT; Pigneux A; Erba HP; Prince GT; Stein AS; Uy GL; Foran JM; Traer E; Stuart RK; Arellano ML; Slack JL; Sekeres MA; Willekens C; Choe S; Wang H; Zhang V; Yen KE; Kapsalis SM; Yang H; Dai D; Fan B; Goldwasser M; Liu H; Agresta S; Wu B; Attar EC; Tallman MS; Stone RM; Kantarjian HM
N Engl J Med; 2018 Jun; 378(25):2386-2398. PubMed ID: 29860938
[TBL] [Abstract][Full Text] [Related]
4. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Watts JM; Baer MR; Yang J; Prebet T; Lee S; Schiller GJ; Dinner SN; Pigneux A; Montesinos P; Wang ES; Seiter KP; Wei AH; De Botton S; Arnan M; Donnellan W; Schwarer AP; Récher C; Jonas BA; Ferrell PB; Marzac C; Kelly P; Sweeney J; Forsyth S; Guichard SM; Brevard J; Henrick P; Mohamed H; Cortes JE
Lancet Haematol; 2023 Jan; 10(1):e46-e58. PubMed ID: 36370742
[TBL] [Abstract][Full Text] [Related]
5. Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Roboz GJ; DiNardo CD; Stein EM; de Botton S; Mims AS; Prince GT; Altman JK; Arellano ML; Donnellan W; Erba HP; Mannis GN; Pollyea DA; Stein AS; Uy GL; Watts JM; Fathi AT; Kantarjian HM; Tallman MS; Choe S; Dai D; Fan B; Wang H; Zhang V; Yen KE; Kapsalis SM; Hickman D; Liu H; Agresta SV; Wu B; Attar EC; Stone RM
Blood; 2020 Feb; 135(7):463-471. PubMed ID: 31841594
[TBL] [Abstract][Full Text] [Related]
6. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m
Cortes J; Jonas BA; Schiller G; Mims A; Roboz GJ; Wei AH; Montesinos P; Ferrell PB; Yee KW; Fenaux P; Schwarer A; Watts JM
Leuk Lymphoma; 2024 Mar; ():1-8. PubMed ID: 38538632
[TBL] [Abstract][Full Text] [Related]
7. Olutasidenib: from bench to bedside.
Venugopal S; Watts J
Blood Adv; 2023 Aug; 7(16):4358-4365. PubMed ID: 37196640
[TBL] [Abstract][Full Text] [Related]
8. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
[TBL] [Abstract][Full Text] [Related]
9. Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
de la Fuente MI; Colman H; Rosenthal M; Van Tine BA; Levacic D; Walbert T; Gan HK; Vieito M; Milhem MM; Lipford K; Forsyth S; Guichard SM; Mikhailov Y; Sedkov A; Brevard J; Kelly PF; Mohamed H; Monga V
Neuro Oncol; 2023 Jan; 25(1):146-156. PubMed ID: 35639513
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy.
Venugopal S; Takahashi K; Daver N; Maiti A; Borthakur G; Loghavi S; Short NJ; Ohanian M; Masarova L; Issa G; Wang X; Carlos BR; Yilmaz M; Kadia T; Andreeff M; Ravandi F; Konopleva M; Kantarjian HM; DiNardo CD
Blood Cancer J; 2022 Jan; 12(1):10. PubMed ID: 35078972
[TBL] [Abstract][Full Text] [Related]
11. Molecular remission and response patterns in patients with mutant-
Stein EM; DiNardo CD; Fathi AT; Pollyea DA; Stone RM; Altman JK; Roboz GJ; Patel MR; Collins R; Flinn IW; Sekeres MA; Stein AS; Kantarjian HM; Levine RL; Vyas P; MacBeth KJ; Tosolini A; VanOostendorp J; Xu Q; Gupta I; Lila T; Risueno A; Yen KE; Wu B; Attar EC; Tallman MS; de Botton S
Blood; 2019 Feb; 133(7):676-687. PubMed ID: 30510081
[TBL] [Abstract][Full Text] [Related]
12. Olutasidenib: First Approval.
Kang C
Drugs; 2023 Mar; 83(4):341-346. PubMed ID: 36848032
[TBL] [Abstract][Full Text] [Related]
13. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
[TBL] [Abstract][Full Text] [Related]
14. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
15. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Lowery MA; Burris HA; Janku F; Shroff RT; Cleary JM; Azad NS; Goyal L; Maher EA; Gore L; Hollebecque A; Beeram M; Trent JC; Jiang L; Fan B; Aguado-Fraile E; Choe S; Wu B; Gliser C; Agresta SV; Pandya SS; Zhu AX; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):711-720. PubMed ID: 31300360
[TBL] [Abstract][Full Text] [Related]
16. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
17. Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.
Pollyea DA; DiNardo CD; Arellano ML; Pigneux A; Fiedler W; Konopleva M; Rizzieri DA; Smith BD; Shinagawa A; Lemoli RM; Dail M; Duan Y; Chyla B; Potluri J; Miller CL; Kantarjian HM
Clin Cancer Res; 2022 Jul; 28(13):2753-2761. PubMed ID: 35046058
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
19. Enasidenib in mutant
Stein EM; DiNardo CD; Pollyea DA; Fathi AT; Roboz GJ; Altman JK; Stone RM; DeAngelo DJ; Levine RL; Flinn IW; Kantarjian HM; Collins R; Patel MR; Frankel AE; Stein A; Sekeres MA; Swords RT; Medeiros BC; Willekens C; Vyas P; Tosolini A; Xu Q; Knight RD; Yen KE; Agresta S; de Botton S; Tallman MS
Blood; 2017 Aug; 130(6):722-731. PubMed ID: 28588020
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
